For example, lanifibranor, a pan-PPAR agonist, has advanced to Phase 3 trials (as of 2025), showing significant reductions in liver fat (up to 45%), fibrosis improvement, and enhanced insulin sensitivity in MASH patients (62). This evidence concerns the gene PPARA and metabolic dysfunction-associated steatohepatitis.